Comparative efficacy and safety of targeted narrowband ultraviolet B, 308-nm excimer laser, and 308-nm excimer lamp in vitiligo: a retrospective study.
{"title":"Comparative efficacy and safety of targeted narrowband ultraviolet B, 308-nm excimer laser, and 308-nm excimer lamp in vitiligo: a retrospective study.","authors":"Thamonwan Tantivithiwate, Chayada Chaiyabutr, Chanisada Wongpraparut, Punyanut Yothachai, Nuttaporn Nuntawisuttiwong, Narumol Silpa-Archa","doi":"10.1080/09546634.2025.2514637","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Data directly comparing targeted narrowband ultraviolet B (NB-UVB), 308-nm excimer laser, and 308-nm excimer lamp for vitiligo are limited.</p><p><strong>Objectives: </strong>We compared the efficacy and safety of these three modalities in vitiligo.</p><p><strong>Methods: </strong>In this retrospective study, we reviewed the medical records of vitiligo patients at the Photodermatology Clinic, Siriraj Hospital. Patients received either targeted NB-UVB (group A), a 308-nm excimer laser (group B), or a 308-nm excimer lamp (group C), administered two to three times per week for at least 3 months. Photographs taken before and after therapy were evaluated. The primary outcome was repigmentation, graded on a five-tier scale: poor (0-25%), fair (26-50%), good (51-75%), very good (76-90%), and excellent (91-100%). The secondary outcome was treatment-related adverse events.</p><p><strong>Results: </strong>No statistically significant differences in efficacy were observed among the three groups, indicated by a very good to excellent response in 42.4% (group A), 17.6% (group B), and 29.4% (group C). Although group A showed higher response rates at 3 and 6 months, differences were not significant. Adverse effects were significantly more frequent in group C.</p><p><strong>Conclusions: </strong>All three devices demonstrated comparable efficacy and promoted rapid repigmentation. However, the excimer lamp had the highest rate of adverse effects.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2514637"},"PeriodicalIF":0.0000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of dermatological treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/09546634.2025.2514637","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/17 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Data directly comparing targeted narrowband ultraviolet B (NB-UVB), 308-nm excimer laser, and 308-nm excimer lamp for vitiligo are limited.
Objectives: We compared the efficacy and safety of these three modalities in vitiligo.
Methods: In this retrospective study, we reviewed the medical records of vitiligo patients at the Photodermatology Clinic, Siriraj Hospital. Patients received either targeted NB-UVB (group A), a 308-nm excimer laser (group B), or a 308-nm excimer lamp (group C), administered two to three times per week for at least 3 months. Photographs taken before and after therapy were evaluated. The primary outcome was repigmentation, graded on a five-tier scale: poor (0-25%), fair (26-50%), good (51-75%), very good (76-90%), and excellent (91-100%). The secondary outcome was treatment-related adverse events.
Results: No statistically significant differences in efficacy were observed among the three groups, indicated by a very good to excellent response in 42.4% (group A), 17.6% (group B), and 29.4% (group C). Although group A showed higher response rates at 3 and 6 months, differences were not significant. Adverse effects were significantly more frequent in group C.
Conclusions: All three devices demonstrated comparable efficacy and promoted rapid repigmentation. However, the excimer lamp had the highest rate of adverse effects.